Altamira Therapeutics Ltd., a biopharmaceutical company, has filed a prospectus related to the disposition of up to 162,548 common shares. These shares may be acquired upon the exercise of warrants issued to a holder on May 1, 2023. The company entered into a Warrant Inducement Agreement on December 7, 2023, which allowed the holder to exercise existing warrants at a reduced price and receive additional warrants. The new warrants, issued on December 15, 2023, are exercisable for six months and two years from their issuance date. Altamira will not receive proceeds from the sale of shares by the selling shareholders, who will cover any underwriting discounts and commissions. The shares are traded on the NASDAQ under the symbol 'CYTO', with a closing price of $3.12 per share on January 5, 2024. The prospectus also highlights the risks involved in investing in Altamira's securities and includes forward-looking statements regarding the company's operations and financial performance.

Altamira Therapeutics Ltd., a biopharmaceutical company, has filed a prospectus related to the disposition of up to 162,548 common shares. These shares may be acquired upon the exercise of warrants issued to a holder on May 1, 2023. The company entered into a Warrant Inducement Agreement on December 7, 2023, which allowed the holder to exercise existing warrants at a reduced price and receive additional warrants. The new warrants, issued on December 15, 2023, are exercisable for six months and two years from their issuance date. Altamira will not receive proceeds from the sale of shares by the selling shareholders, who will cover any underwriting discounts and commissions. The shares are traded on the NASDAQ under the symbol 'CYTO', with a closing price of $3.12 per share on January 5, 2024. The prospectus also highlights the risks involved in investing in Altamira's securities and includes forward-looking statements regarding the company's operations and financial performance.